{
    "root": "35ba2cc7-d1ab-5e85-e063-6394a90a1cd0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glimepiride",
    "value": "20250522",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "GLIMEPIRIDE",
            "code": "6KY687524K"
        }
    ],
    "indications": "Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [\n \n  see Clinical Studies (\n  \n   14.1)\n \n  ]. \n  \n                     Limitations of Use\n                       Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "contraindications": "Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1-2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. ( 2.1 ) Administer with breakfast or first meal of the day. ( 2.1 ) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). ( 2.1 )",
    "warningsAndPrecautions": "Glimepiride tablets USP are available in the following strengths and package sizes:\n  \n•     4 mg (White capsule shaped flat-faced, bevelled edged tablets with breakline on both sides and debossed with 'I' and '4' on either side of breakline        only on one side)\n  \n                  \n                  NDC 60760-845-90 BOTTLES OF 90\n                  \n                     \nStore at 20°C- 25°C (68° - 77°F) [See USP Controlled Room Temperature]\n  \nDispense in well-closed containers with safety closures.",
    "adverseReactions": "Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to:\n                  \n                     Glimepiride or any of the product's ingredients [\n  \n   see Warnings and Precautions (\n   \n    5.2)\n  \n   ].\n \n  \n                     Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives."
}